Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31229450 | 1.00 | MAT2A (0.31) | MAT2AMEN1KMT2ASMN1; SMN2HRH4 | |
| SCHEMBL23577467 | 0.88 | FNTA (0.35) | MAT2ASMN1; SMN2HRH4ADORA2AADORA1 | |
| SCHEMBL23601759 | 0.87 | FNTA (0.34) | MAT2AMEN1KMT2AHRH4 | |
| SCHEMBL23601322 | 0.86 | PTGS2 (0.38) | MAT2A | |
| SCHEMBL31169440 | 0.86 | PTGS2 (0.38) | MAT2A | |
| SCHEMBL23577545 | 0.86 | MAT2A (0.34) | MAT2AMEN1KMT2AHRH4 | |
| SCHEMBL23577556 | 0.85 | ADORA2A (0.33) | MAT2AMEN1KMT2ASMN1; SMN2HRH4 | |
| SCHEMBL23601026 | 0.85 | HRH4 (0.33) | MAT2AMEN1KMT2ASMN1; SMN2HRH4 | |
| SCHEMBL31169447 | 0.85 | HRH4 (0.33) | MAT2AMEN1KMT2ASMN1; SMN2HRH4 | |
| SCHEMBL23601004 | 0.83 | MAT2A (0.36) | MAT2AMEN1KMT2ASMN1; SMN2HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | MAT2A 1551/4885MEN1 4106/4885KMT2A 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.